Wesley Yip, MD, on Urothelial Carcinoma: New Data on Neoadjuvant Gemcitabine and Cisplatin
2022 ASCO Genitourinary Cancers Symposium
Wesley Yip, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II results on neoadjuvant gemcitabine and cisplatin for high-grade upper tract urothelial carcinoma, which was well tolerated and demonstrated a favorable pathologic response rate. Dr. Yip notes that this treatment, given prior to nephroureterectomy, did not significantly delay surgery or increase perioperative complication rates.
The ASCO Post Staff
Massimo Di Maio, MD, of the University of Turin, discusses the Meet-URO12 study, which showed that maintenance niraparib plus best supportive care (BSC) did not prolong progression-free survival, compared with BSC alone, among patients with urothelial cancer that did not progress after first-line platinum-based chemotherapy.
The ASCO Post Staff
Karim Fizazi, PhD, MD, of Gustave Roussy and University of Paris-Saclay, discusses results from a first-in-human phase I/II trial, which showed that administering ODM-208—an oral, nonsteroidal inhibitor of the enzyme CYP11A1—to men with metastatic castration-resistant prostate cancer who were pretreated with abiraterone/enzalutamide and taxanes was effective in blocking the production of steroid hormones. It also showed antitumor activity, especially in men with AR mutation–positive cancers.
The ASCO Post Staff
Neil E. Fleshner, MD, MPH, of the Princess Margaret Cancer Centre, discusses phase II results from the ACDC-RP trial, which indicate a significant tumor response to neoadjuvant abiraterone acetate plus prednisone and leuprolide, with or without cabazitaxel, in patients with high-risk prostate cancer. Those who exhibited either a complete response or minimal residual disease experienced higher rates of progression-free survival. According to Dr. Fleshner, genomic efforts are underway to determine predictors of response.
The ASCO Post Staff
Fred Saad, MD, of the University of Montreal Health Centre, discusses phase III findings demonstrating for the first time the clinical benefits of olaparib plus abiraterone in patients with metastatic castration-resistant prostate cancer, irrespective of their homologous recombination repair mutation status. This regimen led to significantly longer radiographic progression-free survival than placebo plus abiraterone (Abstract 11).
The ASCO Post Staff
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II findings from the BAYOU trial, which studied durvalumab in combination with olaparib for first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma. Because secondary analyses indicated a potential progression-free survival benefit with this combination, there may be a role for PARP inhibitors in the treatment of advanced disease with homologous recombination repair mutation (Abstract 437).
